Results 41 to 50 of about 264,861 (313)

Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA

open access: yesHaematologica, 2016
The PML/RARA fusion protein occurs as a result of the t(15;17) translocation in the acute promyelocytic leukemia subtype of human acute myeloid leukemia.
Karen Keeshan   +9 more
doaj   +1 more source

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies

open access: yesCancers, 2019
This review highlights new findings that have deepened our understanding of the mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia (APL).
N. Noguera   +7 more
semanticscholar   +1 more source

Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia [PDF]

open access: yes, 2000
At diagnosis, clonal gene rearrangement probes {[}retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3 ...
Braun, S.   +5 more
core   +1 more source

Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all

open access: yesLeukemia and Lymphoma, 2019
The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80–90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy.
M. Stahl, M. Tallman
semanticscholar   +1 more source

FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia [PDF]

open access: yes, 2004
Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the ...
Haferlach, Torsten   +4 more
core   +1 more source

Ferritin nanovehicle for targeted delivery of cytochrome C to cancer cells [PDF]

open access: yes, 2019
In this work, we have exploited the unique properties of a chimeric archaeal-human ferritin to encapsulate, deliver and release cytochrome c and induce apoptosis in a myeloid leukemia cell line.
Baiocco, P.   +8 more
core   +2 more sources

Treatment advances have not improved the early death rate in acute promyelocytic leukemia

open access: yesHaematologica, 2012
Early mortality in acute promyelocytic leukemia has been reported to occur in less than 10% of patients treated in clinical trials. This study reports the incidence and clinical features of acute promyelocytic leukemia patients treated at Stanford ...
James Scott McClellan   +6 more
doaj   +1 more source

Role of vitamin A/retinoic acid in regulation of embryonic and adult hematopoiesis [PDF]

open access: yes, 2017
Vitamin A is an essential micronutrient throughout life. Its physiologically active metabolite retinoic acid (RA), acting through nuclear retinoic acid receptors (RARs), is a potent regulator of patterning during embryonic development, as well as being ...
Adamo   +23 more
core   +4 more sources

A giant thrombus in the right atrium of a patient with acute promyelocytic leukemia M3

open access: yesRadiology Case Reports, 2023
Acute promyelocytic leukemia is a special type of acute myeloid leukemia. Patients with this disease are at high risk of complications. Right atrial thrombosis is a rare but potentially serious complication.
Pham Ngoc Thach, MD   +10 more
doaj   +1 more source

Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia

open access: yesOncology and Therapy, 2019
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) that is cytogenetically characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion of the promyelocytic ...
X. Thomas
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy